Immuno-Oncology

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

In the past few years the pace of discovery of effective immunotherapies has accelerated as a consequence of better chemistry and understanding of immune biology.

Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.

Ipilimumab generates antitumor activity in some patients with advanced melanoma whose disease has metastasized to the brain without resulting in unexpected toxicities.

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.

Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process